These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12895273)

  • 1. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use.
    Vichier-Guerre S; Lo-Man R; BenMohamed L; Dériaud E; Kovats S; Leclerc C; Bay S
    J Pept Res; 2003 Sep; 62(3):117-24. PubMed ID: 12895273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
    Lo-Man R; Vichier-Guerre S; Perraut R; Dériaud E; Huteau V; BenMohamed L; Diop OM; Livingston PO; Bay S; Leclerc C
    Cancer Res; 2004 Jul; 64(14):4987-94. PubMed ID: 15256473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate.
    Ganneau C; Simenel C; Emptas E; Courtiol T; Coïc YM; Artaud C; Dériaud E; Bonhomme F; Delepierre M; Leclerc C; Lo-Man R; Bay S
    Org Biomol Chem; 2016 Dec; 15(1):114-123. PubMed ID: 27812586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
    Lo-Man R; Vichier-Guerre S; Bay S; Dériaud E; Cantacuzène D; Leclerc C
    J Immunol; 2001 Feb; 166(4):2849-54. PubMed ID: 11160353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients.
    Rosenbaum P; Artaud C; Bay S; Ganneau C; Campone M; Delaloge S; Gourmelon C; Loirat D; Medioni J; Pein F; Sablin MP; Tredan O; Varga A; Leclerc C
    Cancer Immunol Immunother; 2020 May; 69(5):703-716. PubMed ID: 32034426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
    Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
    Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimization of helper T lymphocyte (HTL) function in vaccine development.
    Alexander J; Fikes J; Hoffman S; Franke E; Sacci J; Appella E; Chisari FV; Guidotti LG; Chesnut RW; Livingston B; Sette A
    Immunol Res; 1998; 18(2):79-92. PubMed ID: 9844827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the Tn epitope.
    Peri F; Cipolla L; Rescigno M; La Ferla B; Nicotra F
    Bioconjug Chem; 2001; 12(3):325-8. PubMed ID: 11353527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
    Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a T-helper peptide from carcinoembryonic antigen.
    Ruiz M; Kobayashi H; Lasarte JJ; Prieto J; Borrás-Cuesta F; Celis E; Sarobe P
    Clin Cancer Res; 2004 Apr; 10(8):2860-7. PubMed ID: 15102695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
    Laubreton D; Bay S; Sedlik C; Artaud C; Ganneau C; Dériaud E; Viel S; Puaux AL; Amigorena S; Gérard C; Lo-Man R; Leclerc C
    Cancer Immunol Immunother; 2016 Mar; 65(3):315-25. PubMed ID: 26847142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short synthetic glycopeptides successfully induce antibody responses to carcinoma-associated Tn antigen.
    Vichier-Guerre S; Lo-Man R; Bay S; Deriaud E; Nakada H; Leclerc C; Cantacuzène D
    J Pept Res; 2000 Feb; 55(2):173-80. PubMed ID: 10784033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
    Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
    Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.
    BenMohamed L; Krishnan R; Longmate J; Auge C; Low L; Primus J; Diamond DJ
    Hum Immunol; 2000 Aug; 61(8):764-79. PubMed ID: 10980387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen.
    Vichier-Guerre S; Lo-Man R; Huteau V; Dériaud E; Leclerc C; Bay S
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3567-70. PubMed ID: 15177475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo.
    del Guercio MF; Alexander J; Kubo RT; Arrhenius T; Maewal A; Appella E; Hoffman SL; Jones T; Valmori D; Sakaguchi K; Grey HM; Sette A
    Vaccine; 1997 Mar; 15(4):441-8. PubMed ID: 9141216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.